articles

Successfully Addressing the Challenges of Glycosylation

Post-translational modification is a critical step in the synthesis of biotherapeutic molecules. Among these alterations to the original naked protein, glycosylation may be the most significant ...

articles

Reducing Fill-Finish Wait Times

iBio has expanded its CDMO service offerings to include independent sterile liquid cGMP fill-finish services to support the preclinical and clinical trial needs of drug developers. This new ...

articles

The Advantage of Plant-based Expression Solutions Around the Globe

iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from ...

articles

Plant-Based Protein Expression for Rapid, Green Bioprocessing

Mammalian cell culture is widely used for biologic drug substance production, but the high cost and long development times pose challenges to the implementation of this technology in many parts ...

articles

Divine Outsourcing Model for Biotechs

Imagine you work at a virtual biopharma with a highly specialized biopharmaceutical ready for advanced development. You contact the one CDMO that you’ve been told undoubtedly has the most ...

articles

Build Biologics Not Barriers

The current trade conflict between the world's biggest economies — the United States and China — has resulted in both countries imposing billions of dollars’ worth of tariffs on each other’s ...

articles

CMOs on Fire

Recently, contract manufacturers have taken the conventional definition of outsourcing, and set it on fire. Traditionally, CMOs provided capacity reservoirs for pharma companies to tap as ...

articles

CDMO Outsourcing Trends

Outsourcing to Contract Development and Manufacturing Organizations (CDMOs) has been on the rise, driven by increasingly complex drug candidates and the expertise they require, and now, ...

articles

In Vivo Glycan Engineering Via the Mannosidase I Inhibitor (Kifunenesine) Improves Efficacy of Rituximab Manufacture in Nicotiana benthamiana Plants

Introduction Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics [1,2] and have been especially beneficial in the treatment of cancer [3]. Since the approval of the ...

articles

Plant Derived Rituximab? iBio Inks "Green" Bioreactor Tech Deal in China

According to the agreement, Delaware, US-based iBio will provide process development and manufacturing services at its Texas facility, and will assist CC-Pharming in preparing a site for ...

articles

Plant-Made E2 Glycoprotein Single-Dose Vaccine Protects Pigs against Classical Swine Fever

Introduction Classical Swine Fever (CSF) is a highly contagious hemorrhagic disease affecting pigs. CSF outbreaks have caused substantial economic damages to the swine industry worldwide, ...

articles

Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies

Introduction Therapeutic glycoproteins represent a predominant disease treatment category among biopharmaceuticals approved or in clinical development. N-linked glycosylation is a very important ...

articles

AzarGen Biotechnologies Granted European Patent for Plant-Made Production of Recombinant Human Surfactant Protein-B

AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), announced that it has received grant status for the patent application: PRODUCTION OF HUMAN PULMONARY SURFACTANT PROTEIN-B IN ...

articles

U.S. Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology

AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa) announced that it has received grant status for the patent application: SYNTHETIC PROMOTER CONSTRUCT FOR TRANSGENE EXPRESSION ...

articles

AzarGen's Case for a Commercial Plant-Made Pharmaceutical Facility in South Africa

AzarGen Biotechnologies, South Africa’s only private plant-based biopharmaceutical company, is imagining a world-class commercial plant-made pharmaceutical facility for South Africa.

articles

Planting the Seed for Speed

You probably won’t find a lot of presidents of successful contract manufacturing organizations gleefully operating the forklift inside the manufacturing plant, but Barry Holtz is no ordinary ...

articles

Techno-Economic Analysis of a Transient Plant-Based Platform for Monoclonal Antibody Production

Introduction Since the commercialization of the first therapeutic monoclonal antibody (mAb) in 1986, this class of biopharmaceutical products has grown exponentially. As of November 2014, ...

articles

Commercial-Scale Biotherapeutics Manufacturing Facility for Plant-Made Pharmaceuticals

Introduction In recent years, the plant‐made pharmaceutical (PMP) community has made significant progress in bringing therapeutics to the clinic: Elelyso™ (Pastores et al., 2014; ...

news

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its ...

events

CPhI Worldwide Bioproduction

November 5-7, 2019
Messe Frankfurt
Frankfurt, Germany

Technology

Why FastPharming ?


FastPharming overcomes issues presented by mammalian expression systems:

  • Speed: Avoids lengthy clone selection and MCB establishment processes by "transfecting at scale"
  • Scale-up: Simple & easy - just plant more plants
  • Sustainability:  Truly "green" manufacturing - no plastic waste when a plant is the "single-use bioreactor"
  • Safety:  Reduced risk of viral contamination
  • Quality:  Accessible, flexible glycosylation controls
  • Cost:  Lower facility CapEx and OpEx in many cases
Learn More

Increased Speed-to-Market


iBio CDMO Services


Process Development

FastPharming optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for your APIs.

cGMP Manufacturing

The FastPharming system transfects at large-scale to easily and reliably deliver biologics in clinical trial or commercial quantities.

Aseptic Fill/Finish

In-line labelling allows serialization of vials and bottles for greater quality assurance of mAbs, viral vectors, and other biologics.

Bioanalytics

An experienced analytical staff provides method development and validation support with expertise in protein characterization using mass spectrometry.

Quality & Regulatory

Quality systems have been carefully constructed to meet cGMP requirements, and iBio can provide regulatory guidance given the team’s experience with therapeutic development.

Factory Solutions

When the time is right, iBio facilitates insourcing by designing and building your own environmentally sustainable FastPharming facilities.

Technology Applications


The FastPharming platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
  • Antigens for subunit vaccine design
  • Virus-like particles (VLP)
  • Lysosomal enzymes
  • Blood factors and cytokines
  • Scaffolds, maturogens and materials for 3D Bioprinting and biofabrication

Contact Us

Interested in applying the power of FastPharming to your project?


iBio offers the CDMO capabilities needed to develop and deliver biologics to market - process development, scale-up, cGMP manufacturing, bioanalytical product characterization, aseptic fill/finish, and quality and regulatory support.

Send us a Message